12.11.2024  21:50:09 Zm. +0,1400 Wolumen Bid21:59:00 Ask21:58:59 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
174,2000EUR +0,08% 0
Obrót: 0.0000
-Wolumen Bid: - -Wolumen Ask: - 85,19 mldEUR - -

Opis działalności

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology.
 

Zarząd & Rada nadzorcza

CEO
Paul Perreault
Zarząd
Alan Wills, Bill Campbell, Bill Mezzanotte, Elizabeth Walker, Greg Boss, John Levy, Mark Hill, Paul McKenzie
Rada nadzorcza
Dr. Brian McNamee, Abbas Hussain, Bruce Brook, Carolyn Hewson, Dr. Megan Clark, Fiona Mead, Marie McDonald, Pascal Soriot, Paul Perreault, Professor Andrew Cuthbertson
 

Dane firmy

Nazwa: CSL Ltd.
Adres: Poplar Road 45,Parkville VIC 3052, Australia
Telefon: +61-3-9389-1911
Fax: +61-3-9389-1434
E-mail: -
Internet: www.csl.com.au/
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 30.06
Free float: 42,01%
Data IPO: 30.05.1994

Relacje inwestorskie

Nazwa: Mark Dehring
Telefon: +61-3-9389-3407
Fax: -
E-mail: mark.dehring@csl.com.au